Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright (TSXV:THRM) submits AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for EUA approval

Brieanna McCutcheon , The Market Online
0 Comments| March 29, 2022

{{labelSign}}  Favorites
{{errorMessage}}

Therma Bright (TSXV:THRM) submits AcuVid™ COVID-19 Rapid Antigen Saliva Test Application for U.S. Food & Drug Administration's EUA.

Tags:

{{labelSign}}  Favorites
{{errorMessage}}


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company